CoChat

Early renin‐angiotensin system intervention is more beneficial than late intervention in delaying end‐stage renal disease in patients with type 2 diabetes

Schievink, B., Kröpelin, T., Mulder, S., Parving, H.‐H., Remuzzi, G., Dwyer, J., Vemer, P., de Zeeuw, D., Lambers Heerspink, H. J. · 2016 · Diabetes, Obesity and Metabolism
Cited by 72

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Aims: To develop and validate a model to simulate progression of diabetic kidney disease ( DKD ) from early onset until end‐stage renal disease ( ESRD ), and to assess the effect of renin‐angiotensin system ( RAS ) intervention in early, intermediate and advanced stages of DKD . Methods: We used data from the BENEDICT , IRMA ‐2, RENAAL and IDNT trials that assessed effects of RAS intervention in patients with type 2 diabetes. We built a model with discrete disease stages based on albuminuria and estimated glomerular filtration rate ( eGFR ). Using survival analyses, we assessed the effect of RAS intervention on delaying ESRD in early [ eGFR >60 ml/min/1.73 m 2 and albumin:creatinine ratio ( ACR ) <30 mg/g], intermediate ( eGFR 30–60 ml/min/1.73 m 2 or ACR 30–300 mg/g) and advanced ( eGFR <30 ml/min/1.73 m 2 or ACR >300 mg/g) stages of DKD for patients in different age groups. Results: For patients at early, intermediate and advanced stage of disease, whose mean age was 60 years and who received placebo, the median time to ESRD was 21.4, 10.8 and 4.7 years, respectively. RAS intervention delayed the predicted time to ESRD by 4.2, 3.6 and 1.4 years, respectively. The benefit of early RAS intervention was more pronounced in younger patients; for example, for patients with a mean age of 45 years, RAS intervention at early, intermediate or advanced stage delayed ESRD by 5.9, 4.0 and 1.1 years versus placebo. Conclusions: RAS intervention early in the course of proteinuric DKD is more beneficial than late intervention in delaying ESRD .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12583

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

Metadata

Authors
Schievink, B., Kröpelin, T., Mulder, S., Parving, H. ‐., Remuzzi, G., Dwyer, J., Vemer, P., de Zeeuw, D., & Lambers Heerspink, H. J.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2015-11-27
Volume
18
Issue
1
Pages
64-71
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W1884587593
Cited by
72
References
14
FWCI
6.98
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.